Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Leukocytes from obese individuals exhibit an impaired SPM signature

  • López Vicario, Cristina
  • Titos Rodríguez, Esther
  • Walker, Mary E.
  • Alcaraz-Quiles, José
  • Casulleras, Mireia
  • Duran Güell, Marta
  • Flores Costa, Roger
  • Pérez Romero, Noelia
  • Forné Bardera, Montserrat
  • Dalli, Jesmond
  • Clària i Enrich, Joan
Specialized proresolving mediators (SPMs) biosynthesized from docosahexaenoic acids (DHAs) including resolvins (Rvs), protectins, and maresins are potent endogenous autacoids that actively resolve inflammation, protect organs, and stimulate tissue regeneration. Our hypothesis was that failure of resolution programs may lead to unremitting inflammation in obesity, contributing to the development of metabolic comorbidities in this condition. Obese individuals with persistent low-grade systemic inflammation showed reduced leukocyte production of the DHA-derived monohydroxy fatty acid 17- hydroxy-DHA (HDHA) and unbalanced formation of SPMs (in particular D-series Rvs) accompanied by enhanced production of proinflammatory lipid mediators such as leukotriene B4. Mechanistic studies attributed this impairment to reduced 15-lipoxygenase (LOX) activity rather than altered DHA cellular uptake. Moreover, leukocytes from obese individuals exhibited decreased 5-LOX levels and reduced 5-LOX Ser271 phosphorylation and distinct intracellular 5-LOX redistribution. However, 15-LOX appears to be the most critical factor for the deficient production of SPMs by obese leukocytes because the formation of D-series Rvs was completely rescued by incubation with the intermediate precursor 17-HDHA. These data provide proof of concept that administration of intermediate precursors of SPM biosynthesis ( e.g., 17-HDHA) could be more efficient in overriding impaired formation of these proresolving lipid mediators in conditions characterized by dysfunctional LOX activity, such as obesity.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Resolvin D2 Attenuates Cardiovascular Damage in Angiotensin II-Induced Hypertension

  • Díaz del Campo, Lucía S.
  • García-Redondo, Ana B.
  • Rodríguez, Cristina
  • Zaragoza, Carlos
  • Duro-Sánchez, Santiago
  • Palmas, Francesco
  • Benito-Bueno, Ángela de
  • Socuéllamos, Paula G.
  • Peraza, Diego A.
  • Rodrigues-Díez, Raquel
  • Valenzuela, Carmen
  • Dalli, Jesmond
  • Salaices, Mercedes
  • Briones, Ana M.
[Background]: Resolution of inflammation is orchestrated by specialized proresolving lipid mediators (SPMs), and this would be impaired in some cardiovascular diseases. Among SPMs, resolvins (Rv) have beneficial effects in cardiovascular pathologies, but little is known about their effect on cardiovascular damage in hypertension., [Methods:]: Aorta, small mesenteric arteries, heart, and peritoneal macrophages were taken from C57BL/6J mice, infused or not with angiotensin II (AngII; 1.44 mg/kg/day, 14 days) in presence or absence of resolvin D2 (RvD2) (100 ng/mice, every second day) starting 1 day before or 7 days after AngII infusion., [Results]: Enzymes and receptors involved in SPMs biosynthesis and signaling were increased in aorta or heart from AngII-infused mice. We also observed a differential regulation of SPMs in heart from these mice. Preventive treatment with RvD2 partially avoided AngII-induced hypertension and protected the heart and large and small vessels against functional and structural alterations induced by AngII. RvD2 increased the availability of vasoprotective factors, modified SPMs profile, decreased cardiovascular fibrosis, and increased the infiltration of pro-resolving macrophages. When administered in hypertensive animals with established cardiovascular damage, RvD2 partially improved cardiovascular function and structure, decreased fibrosis, reduced the infiltration of neutrophils, and shifted macrophage phenotype toward a pro-resolving phenotype., [Conclusions]: There is a disbalance between proinflammatory and resolution mediators in hypertension. RvD2 protects cardiovascular function and structure when administered before and after the development of hypertension by modulating vascular factors, fibrosis and inflammation. Activating resolution mechanisms by treatment with RvD2 may represent a novel therapeutic strategy for the treatment of hypertensive cardiovascular disease., This work is supported by SAF2016-80305P (to M. Salaices and A.M. Briones), SAF2016-75021-R (to C. Valenzuela) funded by MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe”; PID2020-116498RB-I00 (to A.M. Briones), PID2019-104366RB-C21 (to C. Valenzuela) funded by MCIN/AEI/10.13039/501100011033, Grant from Comunidad de Madrid (CM) (B2017/BMD-3676 AORTASANA) FEDER— way to build Europe (to M. Salaices); Grant of the Instituto de Salud Carlos III PI21/01048 (to C. Rodríguez); Grant of Consejo Superior de Investigaciones Cientificas: 2019AEP148 (to C. Valenzuela). The study has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement no. 954798 (to A.M. Briones). R. Rodrigues-Diez was supported by a Juan de la Cierva contract (IJCI-2017-31399). A. de Benito-Bueno is funded by the FPI (BES-2017-080184); P.G. Socuellamos is funded by the FPU (FPU17/02731). J. Dalli is supported by funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant no: 677542) and the Barts Charity (grant no: MGU0343)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Leukocytes from obese individuals exhibit an impaired SPM signature

  • López Vicario, Cristina
  • Titos Rodríguez, Esther
  • Walker, Mary E.
  • Alcaraz-Quiles, José
  • Casulleras, Mireia
  • Duran Güell, Marta
  • Flores Costa, Roger
  • Pérez Romero, Noelia
  • Forné Bardera, Montserrat
  • Dalli, Jesmond
  • Clària i Enrich, Joan
Specialized proresolving mediators (SPMs) biosynthesized from docosahexaenoic acids (DHAs) including resolvins (Rvs), protectins, and maresins are potent endogenous autacoids that actively resolve inflammation, protect organs, and stimulate tissue regeneration. Our hypothesis was that failure of resolution programs may lead to unremitting inflammation in obesity, contributing to the development of metabolic comorbidities in this condition. Obese individuals with persistent low-grade systemic inflammation showed reduced leukocyte production of the DHA-derived monohydroxy fatty acid 17- hydroxy-DHA (HDHA) and unbalanced formation of SPMs (in particular D-series Rvs) accompanied by enhanced production of proinflammatory lipid mediators such as leukotriene B4. Mechanistic studies attributed this impairment to reduced 15-lipoxygenase (LOX) activity rather than altered DHA cellular uptake. Moreover, leukocytes from obese individuals exhibited decreased 5-LOX levels and reduced 5-LOX Ser271 phosphorylation and distinct intracellular 5-LOX redistribution. However, 15-LOX appears to be the most critical factor for the deficient production of SPMs by obese leukocytes because the formation of D-series Rvs was completely rescued by incubation with the intermediate precursor 17-HDHA. These data provide proof of concept that administration of intermediate precursors of SPM biosynthesis ( e.g., 17-HDHA) could be more efficient in overriding impaired formation of these proresolving lipid mediators in conditions characterized by dysfunctional LOX activity, such as obesity.